Help

BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.

To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.

To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.

Employee Benefits

Medicare Part D spending on GLP-1 diabetes drugs surges

April 02, 2024 Reprints

Spending on GLP-1 diabetes drugs under Medicare Part D has surged in recent years, according to a KFF analysis, Fierce Healthcare reports. The study found that spending on Novo Nordisk's Ozempic rose from $56.8m in 2018 to $4.6bn in 2022. The report also noted increased spending on other GLP-1 drugs, with total spending on Ozempic, Novo's Rybelsus, and Eli Lilly's Mounjaro reaching $5.7bn in 2022.

1. Hackers leak stolen data from Change Healthcare on dark web
2. UnitedHealth estimates $1.6 billion loss from Change cyberattack
3. UnitedHealth reports significant data breach; personal health info compromised
4. Ex-NBA player Will Bynum sentenced in insurance fraud scandal
5. Illinois House passes governor’s 'Healthcare Protection Act’
6. Analyst says Cigna, Humana share prices could put merger back on the table

Help

Medicare Part D spending on GLP-1 diabetes drugs surges

Readers Poll

Most Read in Employee Benefits

Sign up now for free access to this article and much more.

If you are already registered with Business Insurance, click here to Login

Please tell us a bit more about yourself in order to continue

About

Advertise

Reprints and Licensing

Resources